Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

Abstract

Systemic mastocytosis (SM) is a rare disease caused by an abnormal mast cell accumulation in various tissues. Two classes of constitutive activating c-kit mutations are found in SM. The most frequent class occurs in the catalytic pocket coding region with substitutions at codon 816 and the other in the intracellular juxtamembrane coding region. Therefore, kinase inhibitors that block mutated c-kit activity might be used as therapeutic agents in SM. Here, we show that STI571 inhibits both wild-type and juxtamembrane mutant c-kit kinase activity, but has no effect on the activity of the D816 V mutant. Accordingly, STI571 selectively decreases the survival of normal mast cell and of mast cell lines either with juxtamembrane c-kit mutations, but not that of tumoral mast cell from patient with SM or of mast cell lines with the D816 V mutation. Therefore, STI571 is not a good candidate to treat SM and specific kinase inhibitors should be designed to inhibit constitutive activating mutations at codon 816.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  • Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E and Mecucci C . (2000). Blood, 95, 726–727.

  • Beslu N, LaRose J, Casteran N, Birnbaum D, Lecocq E, Dubreuil P and Rottapel R . (1996). J. Biol. Chem., 271, 20075–20081.

  • Buchdunger E, Cioffi CL, Law N, Stor FD, Ohno-Jones S, Druker BJ and Lyndon ND . (2000). J. Pharmacol. Exp. Ther., 295, 139–145.

  • Butterfield JH, Weiler D, Dewald G and Gleich GJ . (1988). Leuk. Res., 12, 345–355.

  • Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL . (2001). N. Engl. J. Med., 344, 1031–1037.

  • Hermine O, Mayeux P, Titeux M, Mitjavila MT, Casadevall N, Guichard J, Komatsu N, Suda T, Miura Y and Vainchenker W . (1992). Blood, 80, 3060–3069.

  • Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y, Aozasa K and Nomura T . (2000). Cancer Res., 60, 2345–2347.

  • Horny HP and Valent P . (2001). Leuk. Res., 25, 543–551.

  • Issaad C, Ahmed M, Novault S, Bonnet ML, Bennardo T, Varet B, Vainchenker W and Turhan AG . (2000). Leukemia, 14, 662–670.

  • Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B and Demetri GD . (2001). N Engl. J. Med., 344, 1052–1056.

  • Kitamura Y, Go S and Hatanaka K . (1978). Blood, 52, 447–452.

  • Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH and Linch DC . (2001). Blood, 98, 1752–1759.

  • Longley BJ and Metcalfe DD . (2000). Hematol. Oncol. Clin. North Am., 14, 697–701.

  • Longley BJ, Metcalf DD, Thrap M, Wang X, Tyrrell L, Lu S-Z, Heitzan D, and Tha Y . (1999). Proc. Natl. Acad. Sci. USA, 96, 1609–1614.

  • Longley J, Duffy TP and Kohn S . (1995). J. Am. Acad. Dermatol., 32, 545–561.

  • Marone G, Spadaro G, Granata F and Triggiani M . (2001). Leuk. Res., 25, 583–594.

  • Tsujimura T, Hashimoto K, Kitayama H, Ikeda H, Sugahara H, Matsumura I, Kaisho T, Terada N, Kitamura Y and Kanakura Y . (1999). Blood, 93, 1319–1329.

  • Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y and Kanakura Y . (1996a). Blood, 87, 273–283.

  • Tsujimura T, Moriyama Y, Yamatodani A, Kimura M, Tohya K, Morimoto M, Kitayama H, Kanakura Y and Kitamura Y . (1996b). Am. J. Pathol, 148, 189–200.

  • Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD . (2001). Oncogene, 20, 5054–5058.

  • Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW and Bennett JM . (2001). Leuk. Res., 25, 603–625.

  • Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P and Lechner K . (1992).Blood, 80, 2237–2245.

  • Worobec AS . (2000). Hematol. Oncol. Clin. North Am., 14, 659–687.

  • Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R and Naoe T . (2001). Blood, 97, 2434–2439.

  • Zermati Y, Varet B and Hermine O . (2000). Exp. Hematol., 28, 256–266.

Download references

Acknowledgements

This work was supported by grants from the Association Française pour les Initiatives de Recherche sur le Mastocyte et les Mastocytoses (AFIRMM), the Association pour la Recherche sur le Cancer (ARC) and the Ligue Nationale Contre le Cancer (LNCC). We are indebted to Dr A Turhan (IGR, Villejuif, France) who kindly provided the UT-7-bcr-abl cell line, to Dr Y Kanakura (Tokyo, Japan) who kindly provided FMA-3, Dr K Hashimoto for P815, Ba/F3 Kit G559 and IC2KitV814 cell lines, and to Dr Valent for kindly providing the HMCI cell line (Vienna, Austria). We thank A Tu and D Chez for their help in editing this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Olivier Hermine or Patrice Dubreuil.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zermati, Y., De Sepulveda, P., Féger, F. et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22, 660–664 (2003). https://doi.org/10.1038/sj.onc.1206120

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206120

Keywords

This article is cited by

Search

Quick links